We determined airway mucosal blood flow (Q̇aw) and FEV1 before and after inhaled albuterol in 19 glucocorticosteroid (GS)-naive patients with mild intermittent asthma, and assessed the effects of a 2-wk course of fluticasone propionate (FP; 440 μg daily) on these parameters. Twelve healthy nonsmokers served as controls. Baseline Q̇aw was 55.5 ± 0.7 μl/min/ml (mean ± SE) in the asthmatic subjects and 44.2 ± 0.7 μl/min/ml in the controls; the respective FEV1 values were 2.8 ± 0.2 L and 3.4 ± 0.2 L (p < 0.01 for both parameters). Albuterol increased Q̇aw by 27 ± 3% in the control subjects (p 0.01) but had no effect on Q̇aw in the asthmatic subjects; it increased FEV1 by 7 ± 1% and 6 ± 1% in the two groups, respectively. Q̇aw decreased to 49.2 ± 0.8 μl/min/ml (p < 0.05 versus baseline), and the Q̇aw responsiveness to albuterol was restored (+21 ± 2%; p < 0.05) in the asthmatic subjects after FP. Eleven asthmatic subjects stopped using FP at this time; 2 wk later, their Q̇aw returned to baseline (55.2 ± 0.9 μl/min/ml) and they lost the Q̇aw responsiveness to albuterol. Mean (± SE) FEV1 and FEV1 responsiveness to albuterol were not affected by FP. The GS-sensitive increase in Q̇aw and its hyporesponsiveness to albuterol in asthmatic subjects may be consequences of airway inflammation.
|Original language||English (US)|
|Number of pages||4|
|Journal||American journal of respiratory and critical care medicine|
|State||Published - Jan 1 2000|
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine
- Critical Care and Intensive Care Medicine